Replimune Group Balance Sheet
NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Replimune Group financial position
At the end of fiscal 2026, Replimune Group reported total assets of $332.4 million, down 39.7% from a year earlier against total liabilities of $166.2 million. Shareholders' equity stood at $166.2 million, or 50.0% of assets. The company held $209.0 million in cash and equivalents against $83.3 million of debt, a net cash position of $125.7 million.
The current ratio (current assets divided by current liabilities) was 4.79, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.50.
Summary generated from market data by MetaCap's automated system. Methodology
Replimune Group balance sheet (annual)
| Fiscal year (USD) | FY 20262026-03-31 | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20212021-03-31 | FY 20192020-03-31 | FY 20192019-03-31 | FY 20182018-03-31 | FY 20172017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 209.02M | 111.12M | 74.46M | 146.59M | 105.95M | 182.52M | 59.50M | 25.70M | 17.58M | 20.67M |
| Short-Term Investments | 59.87M | 372.69M | 346.21M | 436.80M | 289.71M | 293.78M | 109.06M | 109.11M | 43.97M | — |
| Inventory | 0 | — | — | — | — | — | — | — | — | — |
| Total Current Assets | 279.12M | 495.88M | 433.67M | 592.60M | 403.98M | 483.75M | 174.25M | 140.98M | 64.70M | — |
| Property, Plant & Equipment | 12.97M | 13.74M | 10.48M | 7.48M | 7.93M | 7.44M | 6.86M | 12.16M | 370.00K | — |
| Total Assets | 332.39M | 551.33M | 487.72M | 646.59M | 461.19M | 543.10M | 234.10M | 154.33M | 65.15M | — |
| Accounts Payable | 6.67M | 12.46M | 2.58M | 5.36M | 3.73M | 2.35M | 3.43M | 7.08M | 1.99M | — |
| Total Current Liabilities | 58.23M | 62.36M | 40.44M | 33.83M | 20.76M | 14.55M | 11.87M | 9.88M | 5.16M | — |
| Long-Term Debt | 83.31M | 46.38M | 44.81M | 28.65M | 0 | — | 9.80M | — | — | — |
| Total Liabilities | 166.23M | 135.49M | 113.21M | 91.30M | 49.96M | 44.37M | 50.38M | 16.47M | 6.86M | — |
| Shareholders' Equity | 166.16M | 415.84M | 374.51M | 555.29M | 411.23M | 498.73M | 183.72M | 137.86M | -28.07M | -11.52M |
| Retained Earnings | -1.26B | -948.58M | -701.28M | -485.49M | -311.20M | -193.17M | -112.30M | -59.77M | -28.93M | — |
| Total Debt | 83.31M | 46.38M | 44.81M | 28.65M | 0 | — | 9.80M | — | — | — |
| Net Cash (Debt) | 185.58M | 437.43M | 375.86M | 554.74M | 395.65M | 476.30M | 158.75M | 134.81M | 61.55M | 20.67M |
| Shares Outstanding | 82.72M | 77.09M | 61.42M | 56.68M | 47.34M | 46.57M | 36.67M | 31.66M | 5.01M | — |
This table shows 10 annual periods of Replimune Group's balance sheet, from FY 2026 back to FY 2017, across 15 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow REPL's reporting calendar. What is a balance sheet?